Searched for
R. ANANTHANARAYANAN
Pharma raw material makers in race to tank up on CXO talentSome of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...- Buy Chemplast Sanmar, target price Rs 650: ICICI SecuritiesChemplast Sanmar, incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 6593.17 Crore) operating in General sect...
- Strides' founder Arun Kumar back to helm the company"The Board of Directors of the Company (Board) accepted Ananth’s resignation and thanked him for his leadership, commitment, enthusiasm, an...
- Strides Pharma banks on acquired Endo portfolio for turnaround of its US businessOn August 6, 2021, Strides announced acquisition of an Endo manufacturing facility in the US along with a basket of ANDAs for $24.9 million...
- Strides Pharma says could take 3-4 qtrs for normalcy of US business hit price erosionThe company on Wednesday reported a net loss of Rs 168 crore in Q2FY22. In the H1FY22, Strides accumulated a net loss of Rs 376.6. Revenues...
- Strides Pharma Science Q1 results: Drug firm posts net loss of Rs 209 crRevenue from operations of the company stood at Rs 688.36 crore for the quarter under consideration. It was Rs 781.79 crore for the same pe...
- Strides Pharma Science to acquire Endo's manufacturing facility in US along with basket of ANDAsStrides said the facility at Chestnut Ridge, New York has an annual capacity of 2 billion units across semi- solids, liquids, nasal sprays ...
- Strides Pharma Science's Puducherry facility successfully completes EU GMP inspectionThe inspection was carried out on April 28, 2021 and the company has now received the renewed GMP (Good Manufacturing Practices) certificat...
- Strides Pharma Science Q2 results: Profit falls 46% to Rs 77 crTotal income stood at Rs 806.42 crore in the quarter under review. It was Rs 728.07 crore in the year-ago period, it added.
- Strides Pharma Science Q1 results: Net profit jumps over 4-fold to Rs 102 crThe company had posted a net profit of Rs 25.36 crore in the corresponding period of the previous fiscal, Strides Pharma Science said in a ...
- Strides Pharma Q4 results: Posts net loss of Rs 206.57 croreThe company's consolidated revenue from operations stood at Rs 618.64 crore for the quarter under consideration.
- Strides Pharma awaiting govt nod for Favipiravir, says CEO R Ananthanarayanan"Our focus is ensuring that we are able to get approvals for all the necessary studies and data in India. We will be able to provide the dr...
- Strides Pharma develops Favipiravir antiviral tablets; drug shows positive outcome in COVID-19 treatmentStrides Pharma Science Ltd on Wednesday said it has developed and commercialised Favipiravir antiviral tablets and stressed that the drug h...
- Buy Strides Pharma, price target Rs 505: Manas JaiswalThe analyst suggested a stoploss at Rs 470 .
- Cipla Q1 profit rises 10% YoY to Rs 451 croreTotal Income from operations stood at Rs 3,939 crore in June quarter.
- Dr Reddy's third quarter net profit rises by 70%Dr Reddy's Laboratories capitalised on the regulatory troubles of Indian rivals to post its highest quarterly income and operating profit d...
- General insurers offer high discounts to corporates as auto business slowsGeneral insurers have started offering deep discounts to corporate clients in the wake of drop in the motor insurance and fall in new indus...
- Insurance industry feels 'motor insurance premium hike is too low to cover losses'The insurance industry termed the decision of the sectoral regulator to increase the motor insurance premium as a step in right direction.
- Dr Reddy's expands operations in UKPharma major Dr Reddy's Laboratories (DRL) today said it has expanded its manufacturing operations in the United Kingdom.
- Innovating For Survival & SuccessCompetition and change can either destroy or bring out the best. And this is true for individuals as well as for companies.
Load More
